Fig. 4
From: Red blood cell-derived arginase release in hemolytic uremic syndrome
Mouse model of Shiga toxin 2 injection: clinical disease, kidney injury and plasma arginase. A Body weight change in mice injected with Shiga toxin 2 (n = 12) or PBS vehicle (n = 7). B Survival of mice injected with Shiga toxin 2 (n = 12) or PBS vehicle (n = 7) during the 7-day long experiment. C Platelet counts in mice injected with Shiga toxin 2 (n = 11, one animal not analyzed, median 1193 × 109/L) or PBS vehicle (n = 7, median 1243 × 109/L). D Plasma urea in mice injected with Shiga toxin 2 (n = 12, median 203 mg/dL) and PBS controls (n = 6; one sample not analyzed, median 44.5 mg/dL). E Plasma arginase 1 levels in mice injected with Shiga toxin 2 (n = 12, median 53.7 ng/mL) and control mice (n = 6; one sample not analyzed, median 14.3 ng/mL). F Plasma arginase activity in mice injected with Shiga toxin 2 (n = 12, median 23.5 µmol urea per L and minute) and control mice (n = 7, median 8.27 µmol urea per L and minute). Comparisons performed using Mann–Whitney U test (panels D-F). Bars in panels C-F denote medians. ns non-significant, PBS phosphate-buffered saline, Stx2 Shiga toxin 2